- Home
- CADL vs EICB Comparison
CADL vs EICB Comparison
Compare CADL & EICB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CADL | EICB |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.8M | N/A |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | CADL | EICB |
|---|---|---|
| Price | $5.59 | $24.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.43 | N/A |
| AVG Volume (30 Days) | ★ 990.7K | N/A |
| Earning Date | 11-13-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.25 | N/A |
| 52 Week High | $13.68 | N/A |
Technical Indicators
Market Signals| Indicator | CADL | EICB |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 42.42 |
| Support Level | $5.48 | $24.90 |
| Resistance Level | $5.98 | $25.00 |
| Average True Range (ATR) | 0.42 | 0.04 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 48.06 | 41.91 |
Price Performance
Historical ComparisonAbout CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
About EICB Eagle Point Income Company Inc. 7.75% Series B Term Preferred Stock Due 2028
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation. The Company seeks to achieve its investment objectives by investing in junior debt tranches of collateralized loan obligations, or "CLOs," that are collateralized by a portfolio consisting of below-investment grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.